Hospital
Jennings American Legion Hospital, INC.
Jennings American Legion Hospital, INC. was paid $5.26M by Medicaid between Jan 2018 and Nov 2022, across 130 billing codes. Its largest line is 99283, emergency room visit (moderate) — 27% of everything it billed.
33Billing provider infoJENNINGS AMERICAN LEGION HOSPITAL, INC.
JENNINGS, LA 70546
JENNINGS, LA 70546
33aNPI1114921160assigned 06/08/2005
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$5.26M
24GClaims214,544
24DCodes billed130
24AFirst – last monthJan 2018 – Nov 2022
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WILLIAMS, DANA controls 14+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 37,889 | $874K | |
| 2019 | 38,145 | $881K | |
| 2020 | 36,643 | $855K | |
| 2021 | 53,853 | $1.43M | |
| 2022 | 48,014 | $1.22M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 27% | 14,875 | 13,925 | $1.43M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 17% | 11,247 | 10,655 | $875K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 2,984 | 2,587 | $707K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.8% | 867 | 809 | $150K |
| 80053 | Comprehensive metabolic panel | 2.4% | 15,245 | 13,726 | $127K |
| 80050 | General health panel | 2.2% | 2,921 | 2,783 | $117K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.2% | 2,755 | 2,594 | $114K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.0% | 5,109 | 4,231 | $104K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.9% | 2,041 | 1,699 | $102K |
| 36415 | Collection of venous blood by venipuncture | 1.6% | 36,233 | 30,097 | $86K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 13,758 | 12,166 | $82K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.5% | 3,686 | 3,347 | $81K |
118 more codes
| 80061 | Lipid panel | 1.5% | 6,193 | $79K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.4% | 2,660 | $75K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.4% | 1,509 | $72K |
| 71045 | Radiologic examination, chest; single view | 1.3% | 2,810 | $68K |
| 87400 | 1.3% | 5,572 | $68K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1.3% | 3,165 | $66K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 1.1% | 813 | $57K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 620 | $49K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,249 | $48K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,249 | $48K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,440 | $43K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,075 | $36K |
| 87088 | <1% | 4,802 | $33K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,776 | $33K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 298 | $27K |
| 85027 | <1% | 4,183 | $25K | |
| 87430 | <1% | 1,698 | $24K | |
| 81001 | <1% | 11,039 | $23K | |
| 87653 | <1% | 648 | $20K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 318 | $19K |
| 87340 | <1% | 2,052 | $19K | |
| 86592 | <1% | 4,630 | $17K | |
| 81025 | <1% | 2,443 | $16K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 901 | $16K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 687 | $15K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 568 | $14K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 86 | $14K |
| 84484 | <1% | 1,720 | $12K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 304 | $12K |
| 82553 | <1% | 1,659 | $11K | |
| G0378 | Hospital observation service, per hour | <1% | 19 | $11K |
| J3410 | Injection, hydroxyzine hcl, up to 25 mg | <1% | 335 | $10K |
| 87070 | <1% | 1,065 | $9K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 59 | $9K |
| 86702 | <1% | 786 | $9K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 115 | $9K |
| 82550 | <1% | 1,970 | $8K | |
| 84439 | <1% | 857 | $7K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 212 | $7K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 14 | $7K |
| 86803 | <1% | 515 | $6K | |
| 86701 | <1% | 789 | $6K | |
| 86850 | <1% | 1,838 | $6K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,066 | $5K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 13 | $5K |
| 86762 | <1% | 385 | $5K | |
| 76937 | <1% | 82 | $5K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 26 | $5K |
| 83880 | <1% | 234 | $5K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 13 | $4K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 88 | $4K |
| 86787 | <1% | 409 | $4K | |
| 83021 | <1% | 282 | $4K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 84 | $4K |
| 86900 | <1% | 1,893 | $4K | |
| 83690 | <1% | 788 | $4K | |
| 87081 | <1% | 654 | $4K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 135 | $4K |
| 86901 | <1% | 1,895 | $4K | |
| 82950 | <1% | 876 | $4K | |
| 0002A | <1% | 104 | $3K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 475 | $3K |
| 76830 | Ultrasound, transvaginal | <1% | 43 | $3K |
| 85730 | <1% | 613 | $2K | |
| 0001A | <1% | 106 | $2K | |
| 74019 | <1% | 77 | $2K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 225 | $2K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 29 | $2K |
| 80055 | <1% | 113 | $2K | |
| 86003 | <1% | 39 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 605 | $2K |
| 85610 | <1% | 595 | $2K | |
| 85384 | <1% | 210 | $2K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 121 | $2K |
| 83735 | <1% | 404 | $2K | |
| 87807 | <1% | 121 | $2K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 477 | $1K |
| 59025 | Fetal non-stress test | <1% | 17 | $1K |
| 80074 | <1% | 29 | $1K | |
| 85660 | <1% | 227 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 706 | $984.35 |
| 82607 | <1% | 68 | $900.53 | |
| 0012A | <1% | 30 | $815.76 | |
| 82150 | <1% | 177 | $772.53 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 38 | $723.90 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,048 | $567.17 |
| 87040 | <1% | 42 | $464.40 | |
| 80320 | <1% | 61 | $456.00 | |
| 0011A | <1% | 13 | $444.96 | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 22 | $431.86 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 60 | $412.49 |
| 82105 | <1% | 27 | $402.48 | |
| 85007 | <1% | 152 | $366.59 | |
| 84481 | <1% | 20 | $268.60 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,411 | $239.88 |
| 84146 | <1% | 12 | $232.56 | |
| 87077 | <1% | 29 | $228.96 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 575 | $182.59 |
| 82728 | <1% | 15 | $177.19 | |
| 81003 | <1% | 67 | $172.93 | |
| 84436 | <1% | 21 | $138.18 | |
| 84479 | <1% | 21 | $132.72 | |
| 86140 | <1% | 30 | $119.14 | |
| 83605 | <1% | 15 | $104.13 | |
| 83540 | <1% | 15 | $90.58 | |
| J3490 | Unclassified drugs | <1% | 140 | $80.45 |
| 82044 | <1% | 17 | $70.38 | |
| 85651 | <1% | 14 | $59.78 | |
| 91300 | <1% | 236 | $31.84 | |
| 91301 | 0% | 40 | $0.00 | |
| 3008F | 0% | 54 | $0.00 | |
| J0461 | Injection, atropine sulfate, 0.01 mg | 0% | 179 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 15 | $0.00 |
| 3074F | 0% | 35 | $0.00 | |
| 1036F | 0% | 24 | $0.00 | |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | 0% | 27 | $0.00 |
| 3078F | 0% | 20 | $0.00 | |
| 3725F | 0% | 53 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWILLIAMS, DANA (CHIEF EXECUTIVE OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Jennings American Legion Hospital INC. | Jennings, LA | $5.05M |
| Ochsner American Legion Hospital LLC | Jennings, LA | $4.63M |
| Jennings American Legion Hospital, INC. | Jennings, LA | $4.58M |
| Ochsner American Legion Hospital LLC | Jennings, LA | $4.26M |
| Ochsner American Legion Hospital LLC | Jennings, LA | $4.02M |
| Ochsner American Legion Hospital LLC | Eunice, LA | $2.96M |
| Jeter Speech Language Pathology Services, LLC | Shreveport, LA | $2.43M |
| Jennings American Legion Hospital INC | Lake Arthur, LA | $931K |
| Ochsner American Legion Hospital LLC | Lake Arthur, LA | $682K |
| Jennings American Legion Hospital, INC. | Jennings, LA | $143K |
| Ochsner American Legion Hospital LLC | Welsh, LA | $59K |
| Ochsner American Legion Hospital LLC | Jennings, LA | $45K |
| Jennings American Legion Hospital INC | Jennings, LA | $24K |
| Dana's Medical Transportation LLC | West Monroe, LA | $21K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.